2024 World Conference on Lung Cancer (WCLC) - Posters-P3.12C.07 Breaking New Ground: Selecting the Best Treatment for Non-Small Cell Lung Cancer According to Mutational Status

P3.12C.07 Breaking New Ground: Selecting the Best Treatment for Non-Small Cell Lung Cancer According to Mutational Status

Back to course

Pdf Summary

The study by Jean Henri Maselli-Schoueri and colleagues focuses on the use of precision medicine to select optimal treatments for Non-Small Cell Lung Cancer (NSCLC) based on mutational status. Recognizing the significance of targeted therapies, this study evaluates treatments through a network meta-analysis of multicenter clinical trials involving immune checkpoint inhibitors (ICIs). Using predefined criteria, 463 articles were screened, of which six trials (POSEIDON, CHECK-MATE 9LA, CHECK-MATE-227, KEYNOTE-042, KEYNOTE-189, and IMPOWER-150) met the inclusion criteria and encompassed 5,069 patients.<br /><br />The research aimed to determine the best treatment regimens according to the mutation status of STK11, KEAP1, and KRAS in NSCLC. Results indicated that ICIs generally offered better benefits than chemotherapy, particularly highlighting the POSEIDON trial's effectiveness, which consistently showed lower numbers needed to treat and higher life years saved across various mutations, except for KRAS mutations that displayed greater variability across studies.<br /><br />Despite the overall superior performance of ICIs, the study found no single trial or medication superior for all mutational statuses, suggesting that multiple factors might influence the effectiveness of these therapies. This underscores the necessity for individualized treatment plans, considering cancer mutations and their unique behaviors in order to enhance patient outcomes.<br /><br />In conclusion, this study emphasizes that ICIs outperform traditional chemotherapy for NSCLC treatment. However, the individual's mutational profile remains a crucial determinant in selecting the most beneficial therapy, advocating for personalized treatment strategies in oncological practice.

Asset Subtitle

Jean Henri Maselli Schoueri

Meta Tag

Speaker Jean Henri Maselli Schoueri

Topic Metastatic NSCLC – Targeted Therapy

Keywords

precision medicine

Non-Small Cell Lung Cancer

NSCLC

mutational status

targeted therapies

immune checkpoint inhibitors

ICIs

network meta-analysis

personalized treatment

oncological practice